Edition:
United Kingdom

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Capital Market

1.85USD
16 Aug 2018
Change (% chg)

$-0.09 (-4.64%)
Prev Close
$1.94
Open
$1.94
Day's High
$1.94
Day's Low
$1.82
Volume
21,244
Avg. Vol
66,316
52-wk High
$55.00
52-wk Low
$1.64

Chart for

About

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based... (more)

Overall

Beta: 3.34
Market Cap(Mil.): $53.11
Shares Outstanding(Mil.): 32.18
Dividend: --
Yield (%): --

Financials

  NVIV.OQ Industry Sector
P/E (TTM): -- 148.53 32.76
EPS (TTM): -0.76 -- --
ROI: -83.17 9.37 14.61
ROE: -86.11 14.70 16.33

BRIEF-Invivo Therapeutics Reports Q1 Loss Per Share Of $3.34

* INVIVO THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

07 May 2018

BRIEF-Invivo Therapeutics Files For Offering Of Up To $8 Mln Shares

* INVIVO THERAPEUTICS HOLDINGS CORP FILES FOR OFFERING OF UP TO $8 MILLION SHARES OF COMMON STOCK, WARRANTS TO PURCHASE SHARES OF COMMON STOCK - SEC FILING Source text (https://bit.ly/2HrYEIM) Further company coverage:

24 Apr 2018

BRIEF-Invivo Therapeutics Announces Reverse Stock Split

* ANTICIPATES REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 5:00 P.M. EASTERN TIME ON APRIL 16, 2018

09 Apr 2018

BRIEF-Invivo Therapeutics Receives FDA Approval For Controlled Trial Of The Neuro-Spinal Scaffold™

* INVIVO THERAPEUTICS RECEIVES FDA APPROVAL FOR PIVOTAL, RANDOMIZED, CONTROLLED TRIAL OF THE NEURO-SPINAL SCAFFOLD™ IN PATIENTS WITH ACUTE SPINAL CORD INJURY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

08 Mar 2018

Earnings vs. Estimates